Clinical Trials Logo

Leukaemia, Myelocytic, Acute clinical trials

View clinical trials related to Leukaemia, Myelocytic, Acute.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01428427 Completed - Clinical trials for Leukaemia, Myelocytic, Acute

Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors

Start date: August 12, 2009
Phase: Phase 1
Study type: Interventional

MEK112111 is a dose-escalation, Phase IB, open-label, single-arm, multi-center study. The primary objective of the study is to determine the recommended dose and regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with gemcitabine in subjects with solid tumors.

NCT ID: NCT01051063 Completed - Clinical trials for Leukaemia, Myelocytic, Acute

Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy

Start date: December 9, 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the clinical activity and safety of a WT1 Antigen-Specific Cancer Immunotherapeutic (WT1 ASCI) as post-induction therapy in adult patients with WT1-positive AML presenting a suboptimal clinical response to induction chemotherapy. The study will also assess whether this treatment induces a specific immune response to the malignancy.

NCT ID: NCT00725283 Completed - Clinical trials for Leukaemia, Myelocytic, Acute

Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)

Start date: October 1, 2008
Phase: Phase 1
Study type: Interventional

This study is being done to evaluate the safety of a WT1 Antigen-Specific Cancer Immunotherapeutic (WT1 ASCI) as post-consolidation therapy in adult patients with WT1-positive Acute Myeloid Leukemia in first complete remission. It will also be analyzed to what extent this treatment induces an immune response, specific to the malignancy.